MedTrace Logo

Hyperopia Correction Using the NTK Optimal Keratoplasty (Opti-K) System

NCT01028937 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-05-09

Study results available
· View outcomes & findings →

Summary

The purpose of this U.S. Clinical Trial on treatment of sighted eyes is to investigate the safety and effectiveness of optimal keratoplasty (Opti-K™) treatments for hyperopia correction using the NTK Enterprises (NTK) Opti-K System.

Conditions

  • Hyperopia

Interventions

DEVICE

Optimal Keratoplasty

Laser treatment in 16 spots at treatment energy densities up to 48 mJ per spot

Sponsors & Collaborators

  • NTK Enterprises, Inc.

    lead INDUSTRY

Principal Investigators

  • Nancy Lockerman · NTK Enterprises

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01028937 on ClinicalTrials.gov